Naturewise Biotech & Medicals (ROCO:4732) Cash-to-Debt : 44.49 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Naturewise Biotech & Medicals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Naturewise Biotech & Medicals's cash to debt ratio for the quarter that ended in Dec. 2023 was 44.49.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Naturewise Biotech & Medicals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Naturewise Biotech & Medicals's Cash-to-Debt or its related term are showing as below:

ROCO:4732' s Cash-to-Debt Range Over the Past 10 Years
Min: 32.98 Med: 77.64 Max: 958.7
Current: 44.49

During the past 13 years, Naturewise Biotech & Medicals's highest Cash to Debt Ratio was 958.70. The lowest was 32.98. And the median was 77.64.

ROCO:4732's Cash-to-Debt is ranked better than
71.43% of 1526 companies
in the Biotechnology industry
Industry Median: 6.315 vs ROCO:4732: 44.49

Naturewise Biotech & Medicals Cash-to-Debt Historical Data

The historical data trend for Naturewise Biotech & Medicals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Naturewise Biotech & Medicals Cash-to-Debt Chart

Naturewise Biotech & Medicals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

32.98

123.34

39.64

98.96

44.49

Naturewise Biotech & Medicals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															39.64	81.01	98.96	101.27	44.49

Competitive Comparison of Naturewise Biotech & Medicals's Cash-to-Debt

For the Biotechnology subindustry, Naturewise Biotech & Medicals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Naturewise Biotech & Medicals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Naturewise Biotech & Medicals's Cash-to-Debt falls into.

Naturewise Biotech & Medicals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Naturewise Biotech & Medicals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	475.263	/	(7.417	+	3.265)
	=	44.49

Naturewise Biotech & Medicals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	475.263	/	(7.417	+	3.265)
	=	44.49

Naturewise Biotech & Medicals (ROCO:4732) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Naturewise Biotech & Medicals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Naturewise Biotech & Medicals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Naturewise Biotech & Medicals (ROCO:4732) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Naturewise Biotech & Medicals Corp (ROCO:4732) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 36, Bade Road, 6th Floor, Section 3, Taipei, TWN, 105

Website

http://www.naturewise.com.tw

Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.

Naturewise Biotech & Medicals (ROCO:4732) Headlines

No Headlines